Материалы доступны только для специалистов сферы здравоохранения. Авторизуйтесь или зарегистрируйтесь.
Новые возможности улучшения продолжительности и качества жизни: эрибулин в лечении больных диссеминированным раком молочной железы
Новые возможности улучшения продолжительности и качества жизни: эрибулин в лечении больных диссеминированным раком молочной железы
Семиглазова Т.Ю., Клюге В.А., Семиглазов В.В. и др. Новые возможности улучшения продолжительности и качества жизни: эрибулин в лечении больных диссеминированным раком молочной железы. Современная Онкология. 2016; 18 (2): 27–33.
________________________________________________
Материалы доступны только для специалистов сферы здравоохранения. Авторизуйтесь или зарегистрируйтесь.
Аннотация
Начиная с 1990-х годов критерием эффективности лечения больных метастатическим/диссеминированным раком молочной железы (мРМЖ) помимо общей выживаемости становится качество жизни – физическое, социальное, психическое и эмоциональное состояние больного. До недавнего времени, в отсутствие стандартов лекарственного лечения после исчерпанных возможностей антрациклин-таксансодержащей терапии мРМЖ, выбор дальнейшей тактики основывался на отдельных нерандомизированных исследованиях и собственной интуиции онколога. Эрибулина мезилат (эрибулин) – химиотерапевтический агент, впервые подтвердивший свою эффективность в двух крупных рандомизированных исследованиях. В 1-м из них были доказаны достоверное увеличение общей выживаемости и сохранение качества жизни в общей популяции больных мРМЖ с прогрессированием заболевания после терапии, включающей антрациклиновые антибиотики и таксаны. Во 2-м исследовании было продемонстрировано преимущество эрибулина у больных с трижды негативным и люминальным В-HER2-негативным подтипами мРМЖ.
Ключевые слова: общая выживаемость, качество жизни, метастатический рак молочной железы, трижды негативный подтип, эрибулин.
Key words: overall survival, quality of life, metastatic breast cancer, triple negative subtype, eribulin.
Ключевые слова: общая выживаемость, качество жизни, метастатический рак молочной железы, трижды негативный подтип, эрибулин.
________________________________________________
Key words: overall survival, quality of life, metastatic breast cancer, triple negative subtype, eribulin.
Полный текст
Список литературы
1. Cardoso F et al. Locally recurrent or metastatic breast cancer: ESMO clinical practice guidelines for diagnosis, treatment and follow-up. Ann Oncol 2015; 22: vi25–vi30.
2. Howlader N, Noone A, Krapcho M et al. SEER Cancer Statistics Review 1975-2010.http://www.seer.cancer.gov/archive/csr/1975_2010/results_merged/sect_04_breast.pdf.-2013.
3. Семиглазов В.Ф., Палтуев Р.М., Семиглазова Т.Ю. и др. Опухоли репродуктивной системы. М.: Рекламно-издательская группа МегаПро, 2013. / Semiglazov V.F., Paltuev R.M., Semiglazova T.Yu. i dr. Opukholi reproduktivnoi sistemy. M.: Reklamno-izdatel'skaia gruppa MegaPro, 2013. [in Russian]
4. Семиглазова Т.Ю., Семиглазов В.В., Филатова Л.В. и др. Качество жизни – важный критерий эффективности таргетной терапии метастатического поражения скелета при раке молочной железы. Опухоли женской репродуктивной системы. 2013; 1–2: 17–22. / Semiglazova T.Yu., Semiglazov V.V., Filatova L.V. i dr. Kachestvo zhizni – vazhnyi kriterii effektivnosti targetnoi terapii metastaticheskogo porazheniia skeleta pri rake molochnoi zhelezy. Opukholi zhenskoi reproduktivnoi sistemy. 2013; 1–2: 17–22. [in Russian]
5. Семиглазова Т.Ю., Жабина А.С., Осипов М.А. и др. Качество жизни – принципиальный критерий эффективности таргетной терапии метастатического HER2-положительного рака молочной железы. Современная Онкология. 2015; 17 (1): 19–24. / Semiglazov V.V., Zhabina A.S., Osipov M.A. i dr. Kachestvo zhizni – printsipial'nyi kriterii effektivnosti targetnoi terapii metastaticheskogo HER2-polozhitel'nogo raka molochnoi zhelezy. Journal of Modern Oncology. 2015; 17 (1): 19–24. [in Russian]
6. Ионова Т.И., Новик А.А., Сухонос Ю.А. Понятие качества жизни больных онкологического профиля. Онкология. 2000; 2 (1–2): 25–8. / Ionova T.I., Novik A.A., Sukhonos Iu.A. Poniatie kachestva zhizni bol'nykh onkologicheskogo profilia. Onkologiia. 2000; 2 (1–2): 25–8. [in Russian]
7. Greenberg P, Hortobagyi G, Smith T et al. Long-term follow-up of patients complete remission following combination chemotherapy for metastatic breast cancer. J Clin Oncol 1996; 14: 2197–205.
8. Belfiglio M, Fanizza C, Tinari N et al. Interuniversitario Nazionale per la Bio-Oncologia (CINBO) Meta-analysis of phase III trials of docetaxel alone or in combination with chemotherapy in metastatic breast cancer. J Cancer Res Clin Oncol 2012; 138: 221–9.
9. Lemieux J, Goodwin P, Bordeleau L et al. Quality-of-life measurement in randomized clinical trials in breast cancer: an updated systematic review (2001–2009). J Nat Cancer Inst 2011; 103: 178–231.
10. Howlader N, Noone A, Krapcho M et al. SEER Cancer Statistics Review, 1975–2010.http://www.seer.cancer.gov/archive/csr/1975_2010/results_merged/sect_04_breast.pdf.
11. Amado F, Lourenço MT, Deheinzelin D. Metastatic breast cancer: do current treatments improve quality of life? A prospective study. Sao Paulo Med J 2006; 124: 203–7.
12. Montazeri А. Health-related quality of life in breast cancer patients: A bibliographic review of the literature from 1974 to 2007. J Experim Clin Cancer Res 2008; 27: 32.
13. Eton D, Cella D, Yost K et al. A combination of distribution and anchor-based approaches determined minimally important differences (MIDs) for four endpoints in a breast cancer scale. J Clin Epidemiol 2004; 57: 898–910.
14. Perry S, Kowalski T, Chang C. Quality of life assessment in women with breast cancer: benefits, acceptability and utilization. Health Qual Life Outcomes 2007; 5: 24–38.
15. Kuznetsov G, Towle MJ, Cheng H et al. Induction of morphological and biochemical apoptosis following prolonged mitotic blockage by halichondrin B macrocyclic ketone analog E7389. Cancer Res 2004; 64: 5760–6.
16. Doherty MK, Morris PG. Eribulin for the treatment of metastatic breast cancer: an update on its safety and efficacy. Int J Womens Health 2015; 7: 47–58.
17. Cortes J et al. Health-related quality of life in patients with locally advanced or metastatic breast cancer treated with eribulinmesylate or capecitabine in an open-label randomized phase 3 trial. Breast Cancer Res Treat 2015; 154 (3): 509–20.
18. Kaufman PA et al. Phase III open-label randomized study of eribulin mesylate versus capecitabine in patients with locally advanced or metastatic breast cancer previously treated with an anthracycline and a taxane. J Clin Oncol 2015; 33 (6): 594–601.
19. Twelves C et al. Efficacy of eribulin in women with metastatic breast cancer: a pooled analysis of two phase 3 studies. Breast Cancer Res Treat 2014; 148 (3): 553–61.
20. Schwartzberg L et al. Quality of life in patients receiving first-line eribulin mesylate for HER2 – locally recurrent or MBC [abstract]. In: Proceedings of the Thirty-Seventh Annual CTRC-AACR San Antonio Breast Cancer Symposium: 2014 Dec 9–13; San Antonio, TX. Philadelphia (PA): AACR; Cancer Res 2015; 75 (9 Suppl): Abstract nr P5-17-02.
21. Aaronson NK, Ahmedzai S, Bergman B et al. The European Organization for Research and Treatment of Cancer QLQ-C30: a quality-of-life instrument for use in international clinical trials in oncology. J Natl Cancer Inst 1993; 85: 365–76.
22. Osoba D, Zee B, Pater J et al. Psychometric properties and responsiveness of the EORTC quality of Life Questionnaire (QLQ-C30) in patients with breast, ovarian and lung cancer. Qual Life Res 1994; 3: 353–64.
23. Sprangers MA, Groenvold M, Arraras JI et al. The European Organization for research and treatment of cancer breast cancer-specific quality-of-life questionnaire module: first results from a three-country field study. J Clin Oncol 1996; 14: 2756–68.
24. EORTC Manual http://www.eortc.be/qol/files/SCManualQLQ-C30.pdf.-2001
25. Martínez E, Zamora P, Servitja S et al. Cascade study: epidemyological analysis of current natural history and treatment patterns of metastatic breast cancer in Spain. Eisai Inc. 2015.
26. Kikuchi Y, Shirakawa K, Kanauchi H et al. A retrospective multicenter observation study about comparative analysis on efficacy of eribulin mesylate with taxane regimens (including combination with bevacizumab) in metastatic breast cancer patients. 2015.
27. Fabi A, Moscetti L, Ciccarese M et al. Eribulin in heavily pretreated metastatic breast cancer patients and clinical/biological feature correlations: impact on the practice. Future oncology. 2015.
28. Velikova G, Hudgens S, Forsythe A et al. Health-related quality of life (HRQoL) and disease symptoms in patients with locally advanced or metastatic breast cancer (MBC) treated with eribulin or capecitabine in a post anthracycline and taxane setting. 2015.
29. Di Maio M, Gallo C, Leighl N et al. Lymptomatic toxicities experienced during anticancer treatment: agreement between patient and physician reporting in three randomized trials. J Clin Oncol 2015; 33: 910–5.
30. Basch E et al. The missing voice of patients in drug-safety reporting. N Engl J Med 2010; 362: 865–9.
31. Basch E, Reeve B, Mitchell S et al. Development of the National Cancer Institute’s patient-reported outcomes version of the common terminology criteria for adverse events (PRO-CTCAE). J Natl Cancer Inst 2014; 106.
32. Brettschneider C, Luhmann D, Raspe H et al. Informative value of Patient Reported Outcomes (PRO) in Health Technology Assessment (HTA). GMS Health Technol Assess 2011; 7: Doc01.
33. Reed E, Simmonds P, Haviland J et al. Quality of life and experience of care in women with metastatic breast cancer: a cross-sectional survey. J Pain Symptom Manage 2011; 43: 747–58.
34. Ballatori E, Roila F et al. Impact of nausea and vomiting on quality of life in cancer patients during chemotherapy. Health Qual Life Outcomes 2003; 1: 46.
2. Howlader N, Noone A, Krapcho M et al. SEER Cancer Statistics Review 1975-2010.http://www.seer.cancer.gov/archive/csr/1975_2010/results_merged/sect_04_breast.pdf.-2013.
3. Semiglazov V.F., Paltuev R.M., Semiglazova T.Yu. i dr. Opukholi reproduktivnoi sistemy. M.: Reklamno-izdatel'skaia gruppa MegaPro, 2013. [in Russian]
4. Semiglazova T.Yu., Semiglazov V.V., Filatova L.V. i dr. Kachestvo zhizni – vazhnyi kriterii effektivnosti targetnoi terapii metastaticheskogo porazheniia skeleta pri rake molochnoi zhelezy. Opukholi zhenskoi reproduktivnoi sistemy. 2013; 1–2: 17–22. [in Russian]
5. Semiglazov V.V., Zhabina A.S., Osipov M.A. i dr. Kachestvo zhizni – printsipial'nyi kriterii effektivnosti targetnoi terapii metastaticheskogo HER2-polozhitel'nogo raka molochnoi zhelezy. Journal of Modern Oncology. 2015; 17 (1): 19–24. [in Russian]
6. Ionova T.I., Novik A.A., Sukhonos Iu.A. Poniatie kachestva zhizni bol'nykh onkologicheskogo profilia. Onkologiia. 2000; 2 (1–2): 25–8. [in Russian]
7. Greenberg P, Hortobagyi G, Smith T et al. Long-term follow-up of patients complete remission following combination chemotherapy for metastatic breast cancer. J Clin Oncol 1996; 14: 2197–205.
8. Belfiglio M, Fanizza C, Tinari N et al. Interuniversitario Nazionale per la Bio-Oncologia (CINBO) Meta-analysis of phase III trials of docetaxel alone or in combination with chemotherapy in metastatic breast cancer. J Cancer Res Clin Oncol 2012; 138: 221–9.
9. Lemieux J, Goodwin P, Bordeleau L et al. Quality-of-life measurement in randomized clinical trials in breast cancer: an updated systematic review (2001–2009). J Nat Cancer Inst 2011; 103: 178–231.
10. Howlader N, Noone A, Krapcho M et al. SEER Cancer Statistics Review, 1975–2010.http://www.seer.cancer.gov/archive/csr/1975_2010/results_merged/sect_04_breast.pdf.
11. Amado F, Lourenço MT, Deheinzelin D. Metastatic breast cancer: do current treatments improve quality of life? A prospective study. Sao Paulo Med J 2006; 124: 203–7.
12. Montazeri А. Health-related quality of life in breast cancer patients: A bibliographic review of the literature from 1974 to 2007. J Experim Clin Cancer Res 2008; 27: 32.
13. Eton D, Cella D, Yost K et al. A combination of distribution and anchor-based approaches determined minimally important differences (MIDs) for four endpoints in a breast cancer scale. J Clin Epidemiol 2004; 57: 898–910.
14. Perry S, Kowalski T, Chang C. Quality of life assessment in women with breast cancer: benefits, acceptability and utilization. Health Qual Life Outcomes 2007; 5: 24–38.
15. Kuznetsov G, Towle MJ, Cheng H et al. Induction of morphological and biochemical apoptosis following prolonged mitotic blockage by halichondrin B macrocyclic ketone analog E7389. Cancer Res 2004; 64: 5760–6.
16. Doherty MK, Morris PG. Eribulin for the treatment of metastatic breast cancer: an update on its safety and efficacy. Int J Womens Health 2015; 7: 47–58.
17. Cortes J et al. Health-related quality of life in patients with locally advanced or metastatic breast cancer treated with eribulinmesylate or capecitabine in an open-label randomized phase 3 trial. Breast Cancer Res Treat 2015; 154 (3): 509–20.
18. Kaufman PA et al. Phase III open-label randomized study of eribulin mesylate versus capecitabine in patients with locally advanced or metastatic breast cancer previously treated with an anthracycline and a taxane. J Clin Oncol 2015; 33 (6): 594–601.
19. Twelves C et al. Efficacy of eribulin in women with metastatic breast cancer: a pooled analysis of two phase 3 studies. Breast Cancer Res Treat 2014; 148 (3): 553–61.
20. Schwartzberg L et al. Quality of life in patients receiving first-line eribulin mesylate for HER2 – locally recurrent or MBC [abstract]. In: Proceedings of the Thirty-Seventh Annual CTRC-AACR San Antonio Breast Cancer Symposium: 2014 Dec 9–13; San Antonio, TX. Philadelphia (PA): AACR; Cancer Res 2015; 75 (9 Suppl): Abstract nr P5-17-02.
21. Aaronson NK, Ahmedzai S, Bergman B et al. The European Organization for Research and Treatment of Cancer QLQ-C30: a quality-of-life instrument for use in international clinical trials in oncology. J Natl Cancer Inst 1993; 85: 365–76.
22. Osoba D, Zee B, Pater J et al. Psychometric properties and responsiveness of the EORTC quality of Life Questionnaire (QLQ-C30) in patients with breast, ovarian and lung cancer. Qual Life Res 1994; 3: 353–64.
23. Sprangers MA, Groenvold M, Arraras JI et al. The European Organization for research and treatment of cancer breast cancer-specific quality-of-life questionnaire module: first results from a three-country field study. J Clin Oncol 1996; 14: 2756–68.
24. EORTC Manual http://www.eortc.be/qol/files/SCManualQLQ-C30.pdf.-2001
25. Martínez E, Zamora P, Servitja S et al. Cascade study: epidemyological analysis of current natural history and treatment patterns of metastatic breast cancer in Spain. Eisai Inc. 2015.
26. Kikuchi Y, Shirakawa K, Kanauchi H et al. A retrospective multicenter observation study about comparative analysis on efficacy of eribulin mesylate with taxane regimens (including combination with bevacizumab) in metastatic breast cancer patients. 2015.
27. Fabi A, Moscetti L, Ciccarese M et al. Eribulin in heavily pretreated metastatic breast cancer patients and clinical/biological feature correlations: impact on the practice. Future oncology. 2015.
28. Velikova G, Hudgens S, Forsythe A et al. Health-related quality of life (HRQoL) and disease symptoms in patients with locally advanced or metastatic breast cancer (MBC) treated with eribulin or capecitabine in a post anthracycline and taxane setting. 2015.
29. Di Maio M, Gallo C, Leighl N et al. Lymptomatic toxicities experienced during anticancer treatment: agreement between patient and physician reporting in three randomized trials. J Clin Oncol 2015; 33: 910–5.
30. Basch E et al. The missing voice of patients in drug-safety reporting. N Engl J Med 2010; 362: 865–9.
31. Basch E, Reeve B, Mitchell S et al. Development of the National Cancer Institute’s patient-reported outcomes version of the common terminology criteria for adverse events (PRO-CTCAE). J Natl Cancer Inst 2014; 106.
32. Brettschneider C, Luhmann D, Raspe H et al. Informative value of Patient Reported Outcomes (PRO) in Health Technology Assessment (HTA). GMS Health Technol Assess 2011; 7: Doc01.
33. Reed E, Simmonds P, Haviland J et al. Quality of life and experience of care in women with metastatic breast cancer: a cross-sectional survey. J Pain Symptom Manage 2011; 43: 747–58.
34. Ballatori E, Roila F et al. Impact of nausea and vomiting on quality of life in cancer patients during chemotherapy. Health Qual Life Outcomes 2003; 1: 46.
2. Howlader N, Noone A, Krapcho M et al. SEER Cancer Statistics Review 1975-2010.http://www.seer.cancer.gov/archive/csr/1975_2010/results_merged/sect_04_breast.pdf.-2013.
3. Семиглазов В.Ф., Палтуев Р.М., Семиглазова Т.Ю. и др. Опухоли репродуктивной системы. М.: Рекламно-издательская группа МегаПро, 2013. / Semiglazov V.F., Paltuev R.M., Semiglazova T.Yu. i dr. Opukholi reproduktivnoi sistemy. M.: Reklamno-izdatel'skaia gruppa MegaPro, 2013. [in Russian]
4. Семиглазова Т.Ю., Семиглазов В.В., Филатова Л.В. и др. Качество жизни – важный критерий эффективности таргетной терапии метастатического поражения скелета при раке молочной железы. Опухоли женской репродуктивной системы. 2013; 1–2: 17–22. / Semiglazova T.Yu., Semiglazov V.V., Filatova L.V. i dr. Kachestvo zhizni – vazhnyi kriterii effektivnosti targetnoi terapii metastaticheskogo porazheniia skeleta pri rake molochnoi zhelezy. Opukholi zhenskoi reproduktivnoi sistemy. 2013; 1–2: 17–22. [in Russian]
5. Семиглазова Т.Ю., Жабина А.С., Осипов М.А. и др. Качество жизни – принципиальный критерий эффективности таргетной терапии метастатического HER2-положительного рака молочной железы. Современная Онкология. 2015; 17 (1): 19–24. / Semiglazov V.V., Zhabina A.S., Osipov M.A. i dr. Kachestvo zhizni – printsipial'nyi kriterii effektivnosti targetnoi terapii metastaticheskogo HER2-polozhitel'nogo raka molochnoi zhelezy. Journal of Modern Oncology. 2015; 17 (1): 19–24. [in Russian]
6. Ионова Т.И., Новик А.А., Сухонос Ю.А. Понятие качества жизни больных онкологического профиля. Онкология. 2000; 2 (1–2): 25–8. / Ionova T.I., Novik A.A., Sukhonos Iu.A. Poniatie kachestva zhizni bol'nykh onkologicheskogo profilia. Onkologiia. 2000; 2 (1–2): 25–8. [in Russian]
7. Greenberg P, Hortobagyi G, Smith T et al. Long-term follow-up of patients complete remission following combination chemotherapy for metastatic breast cancer. J Clin Oncol 1996; 14: 2197–205.
8. Belfiglio M, Fanizza C, Tinari N et al. Interuniversitario Nazionale per la Bio-Oncologia (CINBO) Meta-analysis of phase III trials of docetaxel alone or in combination with chemotherapy in metastatic breast cancer. J Cancer Res Clin Oncol 2012; 138: 221–9.
9. Lemieux J, Goodwin P, Bordeleau L et al. Quality-of-life measurement in randomized clinical trials in breast cancer: an updated systematic review (2001–2009). J Nat Cancer Inst 2011; 103: 178–231.
10. Howlader N, Noone A, Krapcho M et al. SEER Cancer Statistics Review, 1975–2010.http://www.seer.cancer.gov/archive/csr/1975_2010/results_merged/sect_04_breast.pdf.
11. Amado F, Lourenço MT, Deheinzelin D. Metastatic breast cancer: do current treatments improve quality of life? A prospective study. Sao Paulo Med J 2006; 124: 203–7.
12. Montazeri А. Health-related quality of life in breast cancer patients: A bibliographic review of the literature from 1974 to 2007. J Experim Clin Cancer Res 2008; 27: 32.
13. Eton D, Cella D, Yost K et al. A combination of distribution and anchor-based approaches determined minimally important differences (MIDs) for four endpoints in a breast cancer scale. J Clin Epidemiol 2004; 57: 898–910.
14. Perry S, Kowalski T, Chang C. Quality of life assessment in women with breast cancer: benefits, acceptability and utilization. Health Qual Life Outcomes 2007; 5: 24–38.
15. Kuznetsov G, Towle MJ, Cheng H et al. Induction of morphological and biochemical apoptosis following prolonged mitotic blockage by halichondrin B macrocyclic ketone analog E7389. Cancer Res 2004; 64: 5760–6.
16. Doherty MK, Morris PG. Eribulin for the treatment of metastatic breast cancer: an update on its safety and efficacy. Int J Womens Health 2015; 7: 47–58.
17. Cortes J et al. Health-related quality of life in patients with locally advanced or metastatic breast cancer treated with eribulinmesylate or capecitabine in an open-label randomized phase 3 trial. Breast Cancer Res Treat 2015; 154 (3): 509–20.
18. Kaufman PA et al. Phase III open-label randomized study of eribulin mesylate versus capecitabine in patients with locally advanced or metastatic breast cancer previously treated with an anthracycline and a taxane. J Clin Oncol 2015; 33 (6): 594–601.
19. Twelves C et al. Efficacy of eribulin in women with metastatic breast cancer: a pooled analysis of two phase 3 studies. Breast Cancer Res Treat 2014; 148 (3): 553–61.
20. Schwartzberg L et al. Quality of life in patients receiving first-line eribulin mesylate for HER2 – locally recurrent or MBC [abstract]. In: Proceedings of the Thirty-Seventh Annual CTRC-AACR San Antonio Breast Cancer Symposium: 2014 Dec 9–13; San Antonio, TX. Philadelphia (PA): AACR; Cancer Res 2015; 75 (9 Suppl): Abstract nr P5-17-02.
21. Aaronson NK, Ahmedzai S, Bergman B et al. The European Organization for Research and Treatment of Cancer QLQ-C30: a quality-of-life instrument for use in international clinical trials in oncology. J Natl Cancer Inst 1993; 85: 365–76.
22. Osoba D, Zee B, Pater J et al. Psychometric properties and responsiveness of the EORTC quality of Life Questionnaire (QLQ-C30) in patients with breast, ovarian and lung cancer. Qual Life Res 1994; 3: 353–64.
23. Sprangers MA, Groenvold M, Arraras JI et al. The European Organization for research and treatment of cancer breast cancer-specific quality-of-life questionnaire module: first results from a three-country field study. J Clin Oncol 1996; 14: 2756–68.
24. EORTC Manual http://www.eortc.be/qol/files/SCManualQLQ-C30.pdf.-2001
25. Martínez E, Zamora P, Servitja S et al. Cascade study: epidemyological analysis of current natural history and treatment patterns of metastatic breast cancer in Spain. Eisai Inc. 2015.
26. Kikuchi Y, Shirakawa K, Kanauchi H et al. A retrospective multicenter observation study about comparative analysis on efficacy of eribulin mesylate with taxane regimens (including combination with bevacizumab) in metastatic breast cancer patients. 2015.
27. Fabi A, Moscetti L, Ciccarese M et al. Eribulin in heavily pretreated metastatic breast cancer patients and clinical/biological feature correlations: impact on the practice. Future oncology. 2015.
28. Velikova G, Hudgens S, Forsythe A et al. Health-related quality of life (HRQoL) and disease symptoms in patients with locally advanced or metastatic breast cancer (MBC) treated with eribulin or capecitabine in a post anthracycline and taxane setting. 2015.
29. Di Maio M, Gallo C, Leighl N et al. Lymptomatic toxicities experienced during anticancer treatment: agreement between patient and physician reporting in three randomized trials. J Clin Oncol 2015; 33: 910–5.
30. Basch E et al. The missing voice of patients in drug-safety reporting. N Engl J Med 2010; 362: 865–9.
31. Basch E, Reeve B, Mitchell S et al. Development of the National Cancer Institute’s patient-reported outcomes version of the common terminology criteria for adverse events (PRO-CTCAE). J Natl Cancer Inst 2014; 106.
32. Brettschneider C, Luhmann D, Raspe H et al. Informative value of Patient Reported Outcomes (PRO) in Health Technology Assessment (HTA). GMS Health Technol Assess 2011; 7: Doc01.
33. Reed E, Simmonds P, Haviland J et al. Quality of life and experience of care in women with metastatic breast cancer: a cross-sectional survey. J Pain Symptom Manage 2011; 43: 747–58.
34. Ballatori E, Roila F et al. Impact of nausea and vomiting on quality of life in cancer patients during chemotherapy. Health Qual Life Outcomes 2003; 1: 46.
________________________________________________
2. Howlader N, Noone A, Krapcho M et al. SEER Cancer Statistics Review 1975-2010.http://www.seer.cancer.gov/archive/csr/1975_2010/results_merged/sect_04_breast.pdf.-2013.
3. Semiglazov V.F., Paltuev R.M., Semiglazova T.Yu. i dr. Opukholi reproduktivnoi sistemy. M.: Reklamno-izdatel'skaia gruppa MegaPro, 2013. [in Russian]
4. Semiglazova T.Yu., Semiglazov V.V., Filatova L.V. i dr. Kachestvo zhizni – vazhnyi kriterii effektivnosti targetnoi terapii metastaticheskogo porazheniia skeleta pri rake molochnoi zhelezy. Opukholi zhenskoi reproduktivnoi sistemy. 2013; 1–2: 17–22. [in Russian]
5. Semiglazov V.V., Zhabina A.S., Osipov M.A. i dr. Kachestvo zhizni – printsipial'nyi kriterii effektivnosti targetnoi terapii metastaticheskogo HER2-polozhitel'nogo raka molochnoi zhelezy. Journal of Modern Oncology. 2015; 17 (1): 19–24. [in Russian]
6. Ionova T.I., Novik A.A., Sukhonos Iu.A. Poniatie kachestva zhizni bol'nykh onkologicheskogo profilia. Onkologiia. 2000; 2 (1–2): 25–8. [in Russian]
7. Greenberg P, Hortobagyi G, Smith T et al. Long-term follow-up of patients complete remission following combination chemotherapy for metastatic breast cancer. J Clin Oncol 1996; 14: 2197–205.
8. Belfiglio M, Fanizza C, Tinari N et al. Interuniversitario Nazionale per la Bio-Oncologia (CINBO) Meta-analysis of phase III trials of docetaxel alone or in combination with chemotherapy in metastatic breast cancer. J Cancer Res Clin Oncol 2012; 138: 221–9.
9. Lemieux J, Goodwin P, Bordeleau L et al. Quality-of-life measurement in randomized clinical trials in breast cancer: an updated systematic review (2001–2009). J Nat Cancer Inst 2011; 103: 178–231.
10. Howlader N, Noone A, Krapcho M et al. SEER Cancer Statistics Review, 1975–2010.http://www.seer.cancer.gov/archive/csr/1975_2010/results_merged/sect_04_breast.pdf.
11. Amado F, Lourenço MT, Deheinzelin D. Metastatic breast cancer: do current treatments improve quality of life? A prospective study. Sao Paulo Med J 2006; 124: 203–7.
12. Montazeri А. Health-related quality of life in breast cancer patients: A bibliographic review of the literature from 1974 to 2007. J Experim Clin Cancer Res 2008; 27: 32.
13. Eton D, Cella D, Yost K et al. A combination of distribution and anchor-based approaches determined minimally important differences (MIDs) for four endpoints in a breast cancer scale. J Clin Epidemiol 2004; 57: 898–910.
14. Perry S, Kowalski T, Chang C. Quality of life assessment in women with breast cancer: benefits, acceptability and utilization. Health Qual Life Outcomes 2007; 5: 24–38.
15. Kuznetsov G, Towle MJ, Cheng H et al. Induction of morphological and biochemical apoptosis following prolonged mitotic blockage by halichondrin B macrocyclic ketone analog E7389. Cancer Res 2004; 64: 5760–6.
16. Doherty MK, Morris PG. Eribulin for the treatment of metastatic breast cancer: an update on its safety and efficacy. Int J Womens Health 2015; 7: 47–58.
17. Cortes J et al. Health-related quality of life in patients with locally advanced or metastatic breast cancer treated with eribulinmesylate or capecitabine in an open-label randomized phase 3 trial. Breast Cancer Res Treat 2015; 154 (3): 509–20.
18. Kaufman PA et al. Phase III open-label randomized study of eribulin mesylate versus capecitabine in patients with locally advanced or metastatic breast cancer previously treated with an anthracycline and a taxane. J Clin Oncol 2015; 33 (6): 594–601.
19. Twelves C et al. Efficacy of eribulin in women with metastatic breast cancer: a pooled analysis of two phase 3 studies. Breast Cancer Res Treat 2014; 148 (3): 553–61.
20. Schwartzberg L et al. Quality of life in patients receiving first-line eribulin mesylate for HER2 – locally recurrent or MBC [abstract]. In: Proceedings of the Thirty-Seventh Annual CTRC-AACR San Antonio Breast Cancer Symposium: 2014 Dec 9–13; San Antonio, TX. Philadelphia (PA): AACR; Cancer Res 2015; 75 (9 Suppl): Abstract nr P5-17-02.
21. Aaronson NK, Ahmedzai S, Bergman B et al. The European Organization for Research and Treatment of Cancer QLQ-C30: a quality-of-life instrument for use in international clinical trials in oncology. J Natl Cancer Inst 1993; 85: 365–76.
22. Osoba D, Zee B, Pater J et al. Psychometric properties and responsiveness of the EORTC quality of Life Questionnaire (QLQ-C30) in patients with breast, ovarian and lung cancer. Qual Life Res 1994; 3: 353–64.
23. Sprangers MA, Groenvold M, Arraras JI et al. The European Organization for research and treatment of cancer breast cancer-specific quality-of-life questionnaire module: first results from a three-country field study. J Clin Oncol 1996; 14: 2756–68.
24. EORTC Manual http://www.eortc.be/qol/files/SCManualQLQ-C30.pdf.-2001
25. Martínez E, Zamora P, Servitja S et al. Cascade study: epidemyological analysis of current natural history and treatment patterns of metastatic breast cancer in Spain. Eisai Inc. 2015.
26. Kikuchi Y, Shirakawa K, Kanauchi H et al. A retrospective multicenter observation study about comparative analysis on efficacy of eribulin mesylate with taxane regimens (including combination with bevacizumab) in metastatic breast cancer patients. 2015.
27. Fabi A, Moscetti L, Ciccarese M et al. Eribulin in heavily pretreated metastatic breast cancer patients and clinical/biological feature correlations: impact on the practice. Future oncology. 2015.
28. Velikova G, Hudgens S, Forsythe A et al. Health-related quality of life (HRQoL) and disease symptoms in patients with locally advanced or metastatic breast cancer (MBC) treated with eribulin or capecitabine in a post anthracycline and taxane setting. 2015.
29. Di Maio M, Gallo C, Leighl N et al. Lymptomatic toxicities experienced during anticancer treatment: agreement between patient and physician reporting in three randomized trials. J Clin Oncol 2015; 33: 910–5.
30. Basch E et al. The missing voice of patients in drug-safety reporting. N Engl J Med 2010; 362: 865–9.
31. Basch E, Reeve B, Mitchell S et al. Development of the National Cancer Institute’s patient-reported outcomes version of the common terminology criteria for adverse events (PRO-CTCAE). J Natl Cancer Inst 2014; 106.
32. Brettschneider C, Luhmann D, Raspe H et al. Informative value of Patient Reported Outcomes (PRO) in Health Technology Assessment (HTA). GMS Health Technol Assess 2011; 7: Doc01.
33. Reed E, Simmonds P, Haviland J et al. Quality of life and experience of care in women with metastatic breast cancer: a cross-sectional survey. J Pain Symptom Manage 2011; 43: 747–58.
34. Ballatori E, Roila F et al. Impact of nausea and vomiting on quality of life in cancer patients during chemotherapy. Health Qual Life Outcomes 2003; 1: 46.
Авторы
Т.Ю.Семиглазова*1,2, В.А.Клюге1, В.В.Семиглазов1,3, Г.М.Телетаева1, П.В.Криворотько1,2, Г.А.Дашян1, Р.М.Палтуев1, Е.В.Ткаченко1, Р.В.Донских1, В.Ф.Семиглазов1,2
1 ФГБУ НИИ онкологии им. Н.Н.Петрова Минздрава России. 197758, Россия, Санкт-Петербург, пос. Песочный, ул. Ленинградская, д. 68;
2 ГБОУ ВПО Северо-Западный государственный медицинский университет им. И.И.Мечникова Минздрава России. 191015, Россия, Санкт-Петербург, ул. Кирочная, д. 41;
3 ГБОУ ВПО Первый Санкт-Петербургский государственный медицинский университет им. акад. И.П.Павлова Минздрава России. 197022, Россия, Санкт-Петербург, ул. Льва Толстого, д. 6/8
*tsemiglazova@mail.ru
1 N.N.Petrov Research Institute of Oncology of the Ministry of Health of the Russian Federation. 197758, Russian Federation, Saint Petersburg, pos. Pesochnyi, ul. Leningradskaia, d. 68;
2 I.I.Mechnikov State Northwestern Medical University of the Ministry of Health of the Russian Federation. 191015, Russian Federation, Saint Petersburg, ul. Kirochnaia, d. 41;
3 I.M.Pavlov First Saint Petersburg State Medical University of the Ministry of Health of the Russian Federation. 197022, Russian Federation, Saint Petersburg, ul. L'va Tolstogo, d. 6/8
*tsemiglazova@mail.ru
1 ФГБУ НИИ онкологии им. Н.Н.Петрова Минздрава России. 197758, Россия, Санкт-Петербург, пос. Песочный, ул. Ленинградская, д. 68;
2 ГБОУ ВПО Северо-Западный государственный медицинский университет им. И.И.Мечникова Минздрава России. 191015, Россия, Санкт-Петербург, ул. Кирочная, д. 41;
3 ГБОУ ВПО Первый Санкт-Петербургский государственный медицинский университет им. акад. И.П.Павлова Минздрава России. 197022, Россия, Санкт-Петербург, ул. Льва Толстого, д. 6/8
*tsemiglazova@mail.ru
________________________________________________
1 N.N.Petrov Research Institute of Oncology of the Ministry of Health of the Russian Federation. 197758, Russian Federation, Saint Petersburg, pos. Pesochnyi, ul. Leningradskaia, d. 68;
2 I.I.Mechnikov State Northwestern Medical University of the Ministry of Health of the Russian Federation. 191015, Russian Federation, Saint Petersburg, ul. Kirochnaia, d. 41;
3 I.M.Pavlov First Saint Petersburg State Medical University of the Ministry of Health of the Russian Federation. 197022, Russian Federation, Saint Petersburg, ul. L'va Tolstogo, d. 6/8
*tsemiglazova@mail.ru
Цель портала OmniDoctor – предоставление профессиональной информации врачам, провизорам и фармацевтам.